Summary of important studies of laser interstitial thermal therapy (LITT) included within this review paper
| Study . | (n) . | Study Type . | Finding . |
|---|---|---|---|
| Kamath et al. 20193 | 54 | Retrospective | There was no significant difference in steroid use at 1 month, progression-free survival or overall survival in patients treated with LITT for newly discovered or recurrent glioblastoma multiforme tumors |
| Hong et al. 20194 | 75 | Retrospective | Progression-free survival, overall survival and number of patients remaining on steroids were not significantly different between patients who underwent LITT or craniotomy for symptomatic lesions |
| Smith et al. 20165 | 25 | Retrospective | Mental health and vitality scores were higher at 1 year after LITT for biopsy-proven radiation necrosis |
| Hernandez et al. 20186 | 59 | Retrospective | Local control of radiation necrosis lesions occurred in 83.1% of patients, with 10 patients requiring further intervention for their lesion |
| Ahluwalia et al. 20197 | 42 | Prospective multi-center study | Progression was seen in 25% of completely ablated brain metastases, whereas 62.5% of incompletely ablated brain metastases progressed |
| Salehi et al. 20188 | 25 | Retrospective | Progression-free survival was significantly longer in patients with a brain metastasis > 5.62 cm3 (median volume in the study) and >97% lesion ablated |
| Ali et al. 20189 | 3 | Retrospective | Patients who received bevacizumab within 30 days after LITT did not experience any complications, although all died due to disease progression |
| Study . | (n) . | Study Type . | Finding . |
|---|---|---|---|
| Kamath et al. 20193 | 54 | Retrospective | There was no significant difference in steroid use at 1 month, progression-free survival or overall survival in patients treated with LITT for newly discovered or recurrent glioblastoma multiforme tumors |
| Hong et al. 20194 | 75 | Retrospective | Progression-free survival, overall survival and number of patients remaining on steroids were not significantly different between patients who underwent LITT or craniotomy for symptomatic lesions |
| Smith et al. 20165 | 25 | Retrospective | Mental health and vitality scores were higher at 1 year after LITT for biopsy-proven radiation necrosis |
| Hernandez et al. 20186 | 59 | Retrospective | Local control of radiation necrosis lesions occurred in 83.1% of patients, with 10 patients requiring further intervention for their lesion |
| Ahluwalia et al. 20197 | 42 | Prospective multi-center study | Progression was seen in 25% of completely ablated brain metastases, whereas 62.5% of incompletely ablated brain metastases progressed |
| Salehi et al. 20188 | 25 | Retrospective | Progression-free survival was significantly longer in patients with a brain metastasis > 5.62 cm3 (median volume in the study) and >97% lesion ablated |
| Ali et al. 20189 | 3 | Retrospective | Patients who received bevacizumab within 30 days after LITT did not experience any complications, although all died due to disease progression |
Summary of important studies of laser interstitial thermal therapy (LITT) included within this review paper
| Study . | (n) . | Study Type . | Finding . |
|---|---|---|---|
| Kamath et al. 20193 | 54 | Retrospective | There was no significant difference in steroid use at 1 month, progression-free survival or overall survival in patients treated with LITT for newly discovered or recurrent glioblastoma multiforme tumors |
| Hong et al. 20194 | 75 | Retrospective | Progression-free survival, overall survival and number of patients remaining on steroids were not significantly different between patients who underwent LITT or craniotomy for symptomatic lesions |
| Smith et al. 20165 | 25 | Retrospective | Mental health and vitality scores were higher at 1 year after LITT for biopsy-proven radiation necrosis |
| Hernandez et al. 20186 | 59 | Retrospective | Local control of radiation necrosis lesions occurred in 83.1% of patients, with 10 patients requiring further intervention for their lesion |
| Ahluwalia et al. 20197 | 42 | Prospective multi-center study | Progression was seen in 25% of completely ablated brain metastases, whereas 62.5% of incompletely ablated brain metastases progressed |
| Salehi et al. 20188 | 25 | Retrospective | Progression-free survival was significantly longer in patients with a brain metastasis > 5.62 cm3 (median volume in the study) and >97% lesion ablated |
| Ali et al. 20189 | 3 | Retrospective | Patients who received bevacizumab within 30 days after LITT did not experience any complications, although all died due to disease progression |
| Study . | (n) . | Study Type . | Finding . |
|---|---|---|---|
| Kamath et al. 20193 | 54 | Retrospective | There was no significant difference in steroid use at 1 month, progression-free survival or overall survival in patients treated with LITT for newly discovered or recurrent glioblastoma multiforme tumors |
| Hong et al. 20194 | 75 | Retrospective | Progression-free survival, overall survival and number of patients remaining on steroids were not significantly different between patients who underwent LITT or craniotomy for symptomatic lesions |
| Smith et al. 20165 | 25 | Retrospective | Mental health and vitality scores were higher at 1 year after LITT for biopsy-proven radiation necrosis |
| Hernandez et al. 20186 | 59 | Retrospective | Local control of radiation necrosis lesions occurred in 83.1% of patients, with 10 patients requiring further intervention for their lesion |
| Ahluwalia et al. 20197 | 42 | Prospective multi-center study | Progression was seen in 25% of completely ablated brain metastases, whereas 62.5% of incompletely ablated brain metastases progressed |
| Salehi et al. 20188 | 25 | Retrospective | Progression-free survival was significantly longer in patients with a brain metastasis > 5.62 cm3 (median volume in the study) and >97% lesion ablated |
| Ali et al. 20189 | 3 | Retrospective | Patients who received bevacizumab within 30 days after LITT did not experience any complications, although all died due to disease progression |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
